- Company
- Generics for Betmiga competition gets fierce
- by Kim, Jin-Gu Jul 28, 2020 06:37am
- Full-fledged competition began in the generic market of “Betmiga (Mirabegron),” which has annual outpatient prescriptions of &8361;65 billion. Hanmi and Chong Kun Dang, which received generic for exclusivity, recently released generics. The two companies plan to focus on expanding the market until February next year when the trial perio
- Company
- MFDS collects acetaminophen to confirm impurity
- by Chon, Seung-Hyun Jul 28, 2020 06:33am
- The South Korean government is initiating an investigation on impurity contamination in an active pharmaceutical ingredient (API), acetaminophen. As the risk of impurity contamination in API manufactured by a Chinese manufacturer was raised recently, the government started proactively collecting and testing the API used in Korea. If the wid
- Company
- MFDS to tighten up regulations on appetite suppressant
- by jung, sae-im Jul 27, 2020 06:31am
- The South Korean health authority drafted regulations preventing the abuse of psychoactive appetite suppressants. The draft contains high-level of regulations like adopting active substance designation system used in narcotics control, which can heavily impact the relevant industry. According to pharmaceutical industry sources on July 2
- Company
- First-line Cyramza+Tarceva combo to treat NSLCL in Korea
- by Eo, Yun-Ho Jul 24, 2020 06:25am
- A targeted therapy combination option could be introduced to the non-small cell lung cancer (NSCLC) treatment area. The pharmaceutical industry sources reported, Lilly Korea has recently submitted an application to expand the drug’s indication to treat patients with NSCLC as a first-line combination treatment of vascular endothelial gro
- Company
- Genexine, promotes clinical trial of Hyleukin-7·Opdivo
- by An, Kyung-Jin Jul 24, 2020 06:24am
- Genexine announced on the 22nd that the anti-cancer drug 'Hyleukin-7' (GX-I7), which is under development with NeoImmuneTech, has entered a co-clinical trial with BMS. According to Genexine, phase II clinical trial that recently administered 'GX-I7' and BMS' immune checkpoint inhibitor 'Opdivo' (Nivolumab) in patients with metastatic gastr
- Company
- 4 years on KOSPI Samsung Biologics to earn over KRW 1 tln
- by Lee, Seok-Jun Jul 24, 2020 06:24am
- Samsung Biologics is now in full swing to generate sales. This year’s sales are projected to exceed 1 trillion won as its profitability improves every year. In the first half of the year, the Korean company has inked a few contracts valued approximately at 1.8 trillion won, which would propel the company forward as future growth engine. The
- Company
- Sales for Antibiotic Rx declined significantly
- by Chon, Seung-Hyun Jul 23, 2020 06:11am
- The prominent feature of the outpatient Rx drug market in the first half is that it was sluggish than in 2Q. COVID-19 also had an impact. When the fears of COVID-19 spread in February and March, the analysis revealed that patients had been receiving long-term prescriptions in advance and that prescription performance was poor. The prescr
- Company
- Asthma drug montelukast prescription plummets amid COVID-19
- by Kim, Jin-Gu Jul 23, 2020 06:11am
- The prescription volume of montelukast widely used for asthma and allergy treatment has plummeted. The industry experts analyze the market was heavily impacted by pediatric and adolescent patients’ scarce visit to hospital amid COVID-19, and also by the U.S. Food and Drug Administration (FDA) labeling the top level the adverse reaction
- Company
- Ildong expands collaboration with Evotec
- by Kim, Jin-Gu Jul 23, 2020 06:11am
- Ildong announced on the 21st that it will expand its cooperation with global new drug development company Evotec to conduct clinical trials on NASH (non-alcoholic steatohepatitis) treatment research project 'ID11903'. Evotech's drug research platform, 'INDiGO', is used to conduct various tasks necessary for clinical entry, such as nonclini
- Company
- Rx amount for Choline alfoscerate is the largest ever
- by Chon, Seung-Hyun Jul 22, 2020 06:16am
- Rx market for brain function-enhancing drug 'Choline alfoscerate' has grown significantly. Despite the controversy over the effectiveness and the bad news of COVID-19, the rate was over &8361;200 billion the first half of this year and continued to rise. The monthly prescription amount was &8361;40 billion. Not only Daewoong Bio and Chon
